Carmanah Minerals Corp is in the exploration stage company. It engages in the exploration and development of mineral properties in Canada. The projects in which the company holds an interest are Walker Project (Uranium), Hare Hill Project (Pluton), and Loljuh Project.
相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
100.0%
暂无批准数据
- Aprea Therapeutics has appointed industry veteran Eugene Kennedy, MD, as Chief Medical Advisor following early clinical proof-of-concept demonstrated in its ongoing Phase 1 study of WEE1 inhibitor APR-1051. - Dr. Kennedy brings over 20 years of oncology clinical development experience and has previously served as Chief Medical Officer at multiple biotechnology companies including Carisma Therapeutics and Galera Therapeutics. - The appointment strengthens Aprea's clinical leadership as the company advances dose escalation and refines patient selection for its DNA damage response program targeting multiple solid tumor types.
- Percheron Therapeutics has appointed Dr Eugene Kennedy as Chief Medical Officer and Valentina Dubljevic as Chief Technology Officer to strengthen leadership ahead of HMBD-002's phase II trial. - HMBD-002 is a monoclonal antibody targeting the immune checkpoint regulator VISTA that has completed phase I testing with favorable safety and tolerability data. - The company plans to commence recruitment for the phase II trial of HMBD-002 in calendar year 2026, marking a critical advancement in the oncology program. - Dr Kennedy brings over a decade of immuno-oncology experience from roles at Johns Hopkins and Carisma Therapeutics, while Dubljevic will focus on manufacturing and regulatory compliance.
- The anti-GPC3 targeted therapies market is expected to surge significantly by 2040, driven by increasing cancer incidence and clinical pipeline activity across hepatocellular carcinoma, non-small cell lung cancer, and gastric cancer. - AstraZeneca presented promising data from the RHEA-1 first-in-human study of AZD9793, a first-in-class CD8-guided T cell engager targeting GPC3-positive advanced or metastatic HCC at ASCO 2025. - Bayer initiated a Phase I clinical trial for 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical designed to treat GPC3-expressing tumors in patients with advanced HCC. - Key pipeline therapies include ECT204 from Eureka Therapeutics, currently under evaluation in the ARYA-3 Phase I/II trial for GPC3-positive HCC patients.
- Carisma Therapeutics and OrthoCellix have entered into a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company focused on orthopedic diseases. - The combined company will advance NeoCart®, an autologous cartilage implant technology that uses patient cells to repair knee articular cartilage defects, into Phase 3 trials by end of 2025. - The merger includes $25 million in concurrent financing, with OrthoCellix stockholders expected to own approximately 90% of the combined company upon closing. - NeoCart® has received FDA Regenerative Medicine Advanced Therapy designation and utilizes a 3D scaffold platform to grow chondrocytes that produce adolescent-like cartilage.
- The global RNA therapy clinical trials market is projected to grow from $2.85 billion in 2024 to $4.16 billion by 2034, with a CAGR of 3.85%, driven by advancements in mRNA, siRNA, and antisense oligonucleotide-based therapies. - Over 80 companies are currently evaluating more than 100 RNA therapies across various development stages, with significant activity in rare diseases, oncology, and genetic disorders. - Recent breakthroughs include FDA clearance for the first CRISPR/Cas13 RNA-editing therapy for neovascular age-related macular degeneration and promising results for RNA therapies targeting rare muscular dystrophies.
- Resolution Therapeutics raised $85 million in Series B financing to advance RTX001, a macrophage therapy, into clinical trials for end-stage liver disease. - RTX001 is an engineered, pro-regenerative macrophage therapy designed to reduce inflammation and fibrosis in patients with severe liver disease, offering a potential alternative to liver transplants. - The Phase 1/2 EMERALD clinical trial is set to begin patient recruitment in Q4 2024, evaluating the safety and efficacy of RTX001 in patients who have recovered from hepatic decompensation. - Resolution Therapeutics is also exploring the application of its macrophage therapy in other fibrotic diseases, such as graft-vs-host-disease and lung fibrosis, expanding its therapeutic pipeline.
